USA - NASDAQ:VIR - US92764N1028 - Common Stock
Overall VIR gets a fundamental rating of 3 out of 10. We evaluated VIR against 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VIR as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, VIR is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -46.14% | ||
ROE | -58.07% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 96.08% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -0.09 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 7.01 | ||
Quick Ratio | 7.01 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
6.12
-0.15 (-2.39%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 44.75 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.9 | ||
P/tB | 0.92 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -46.14% | ||
ROE | -58.07% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 96.08% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 77.21% | ||
Cap/Sales | 47% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 7.01 | ||
Quick Ratio | 7.01 | ||
Altman-Z | -0.09 |